Novavax, Inc. (LON:0A3S)

Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of GBP 812.66 million. The enterprise value is 423.12 million.

Market Cap	812.66M
Enterprise Value	423.12M

Important Dates

The last earnings date was Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	162.50M
Shares Outstanding	n/a
Shares Change (YoY)	+16.16%
Shares Change (QoQ)	-8.39%
Owned by Insiders (%)	0.51%
Owned by Institutions (%)	52.14%
Float	134.90M

Valuation Ratios

The trailing PE ratio is 3.20.

PE Ratio	3.20
Forward PE	n/a
PS Ratio	1.03
PB Ratio	-6.97
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.23, with an EV/FCF ratio of -1.48.

EV / Earnings	1.66
EV / Sales	0.52
EV / EBITDA	1.23
EV / EBIT	1.33
EV / FCF	-1.48

Financial Position

The company has a current ratio of 2.27

Current Ratio	2.27
Quick Ratio	1.85
Debt / Equity	n/a
Debt / EBITDA	0.56
Debt / FCF	-0.65
Interest Coverage	13.84

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	18.01%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	55.57%
Revenue Per Employee	831,971
Profits Per Employee	267,056
Employee Count	952
Asset Turnover	0.74
Inventory Turnover	39.01

Taxes

In the past 12 months, Novavax has paid 6.65 million in taxes.

Income Tax	6.65M
Effective Tax Rate	2.55%

Stock Price Statistics

The stock price has decreased by -10.34% in the last 52 weeks. The beta is 2.30, so Novavax's price volatility has been higher than the market average.

Beta (5Y)	2.30
52-Week Price Change	-10.34%
50-Day Moving Average	8.27
200-Day Moving Average	7.50
Relative Strength Index (RSI)	26.63
Average Volume (20 Days)	43,921

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.39

Income Statement

In the last 12 months, Novavax had revenue of GBP 792.04 million and earned 254.24 million in profits. Earnings per share was 1.54.

Revenue	792.04M
Gross Profit	470.63M
Operating Income	310.09M
Pretax Income	260.89M
Net Income	254.24M
EBITDA	336.13M
EBIT	310.09M
Earnings Per Share (EPS)	1.54

Balance Sheet

The company has 567.55 million in cash and 186.83 million in debt, giving a net cash position of 380.71 million.

Cash & Cash Equivalents	567.55M
Total Debt	186.83M
Net Cash	380.71M
Net Cash Per Share	n/a
Equity (Book Value)	-116.55M
Book Value Per Share	-0.72
Working Capital	405.24M

Cash Flow

In the last 12 months, operating cash flow was -281.45 million and capital expenditures -4.03 million, giving a free cash flow of -285.48 million.

Operating Cash Flow	-281.45M
Capital Expenditures	-4.03M
Free Cash Flow	-285.48M
FCF Per Share	n/a

Margins

Gross margin is 59.42%, with operating and profit margins of 39.15% and 32.10%.

Gross Margin	59.42%
Operating Margin	39.15%
Pretax Margin	32.94%
Profit Margin	32.10%
EBITDA Margin	42.44%
EBIT Margin	39.15%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.16%
Shareholder Yield	-16.16%
Earnings Yield	31.28%
FCF Yield	-35.13%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05.

Last Split Date	May 10, 2019
Split Type	Reverse
Split Ratio	0.05

Scores

Novavax has an Altman Z-Score of -2.23 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.23
Piotroski F-Score	5